US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

52wk High:84.98

52wk Low:23.15

Shares:79.95M

Float Shares:74.86M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1374

EPS(LYR):-1.6740

ROE:553.30%

ROA:-13.71%

PB:178.02

PE(LYR):-50.72

Loading ...

Overview Company News Filings

BeOne Medicines Is Maintained at Buy by Citigroup

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

BeOne Medicines price target raised to $390 from $383 at Morgan Stanley

RBC Capital Adjusts Price Target on BeOne Medicines to $395 From $374, Maintains Outperform Rating

MT Newswires Live

BeOne Medicines Is Maintained at Market Outperform by Citizens

BeOne Medicines price target raised to $396 from $348 at Citizens JMP

BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating

BeOne Medicines Returns to Profit in Q3 as Revenue Jumps 41%; Shares Rise 3%

MT Newswires Live

BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; Lifts Lower-End of Fiscal 2025 Revenue Outlook Range

MT Newswires Live

GUIDANCE: (ONC) BeOne Medicines Expects Full Year 2025 Sales Range $5.1B - $5.3B, vs. FactSet Est of $5.22B

MT Newswires Live

What Everest Medicines (SEHK:1952)'s Exclusive VIS-101 Ophthalmology License Means for Shareholders

Simply Wall St.

Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal

Simply Wall St.

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?

Market Chatter: Novartis Considers Adding More Medicines to Direct-to-Patient Platform in US

MT Newswires Live

GSK Says European Medicines Agency Grants Orphan Drug Designation for Lung Cancer Therapy

MT Newswires Live

SSY Group Wins Chinese Government Bid to Supply Medicines to Healthcare Facilities

MT Newswires Live

SSY Group’s Products Selected in National Medicines Procurement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582383116","title":"BeOne Medicines Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383116","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383116?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:40","pubTimestamp":1762810800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 16:40 ET (21:40 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582793988","title":"MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology","url":"https://stock-news.laohu8.com/highlight/detail?id=2582793988","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582793988?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"LONDONandNEW YORK, Nov.  10, 2025  (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collab","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9502e9704f0d2a25f1fd7559c85b01d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184353/0/en/MeiraGTx-Enters-into-Strategic-Collaboration-with-Eli-Lilly-and-Company-to-Develop-and-Commercialize-Genetic-Medicines-in-Ophthalmology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","LU0114720955.EUR","BK4533","BK4516","LU0354030511.USD","LU2471134796.USD","LU2023250504.SGD","LU0354030438.USD","MDCO","LU1989771016.USD","IE00BK4W5M84.HKD","LU2750360997.AUD","LU0320765992.SGD","BK4007","IE00BK4W5L77.USD","LU2750360641.GBP","IE00B1XK9C88.USD","LU2471134523.USD","LLY","LU2089984988.USD","SGXZ51526630.SGD","LU2468319806.SGD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU1917777945.USD","LU0820561909.HKD","LU1974910355.USD","LU0106261372.USD","LU2112291526.USD","LU1069344957.HKD","LU2108987350.USD","IE0009355771.USD","IE00BWXC8680.SGD","SG9999017495.SGD","LU1623119135.USD","LU2461242641.AUD","LU0689472784.USD","LU0786609619.USD","LU0058720904.USD","LU0672654240.SGD","LU1035775433.USD","LU0203201768.USD","LU0316494557.USD","LU1712237335.SGD","LU2264538146.SGD","LU1057294990.SGD","SG9999013999.USD","LU1127390331.HKD","LU0079474960.USD","LU0094547139.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2582269868","title":"Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582269868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582269868?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:57","pubTimestamp":1762765054,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $385.00. Wang covers the Hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581838079","title":"BeOne Medicines price target raised to $390 from $383 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2581838079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581838079?lang=en_us&edition=fundamental","pubTime":"2025-11-08 01:55","pubTimestamp":1762538122,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $390 from $383 and keeps an Overweight rating on the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-price-target-raised-to-390-from-383-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-price-target-raised-to-390-from-383-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581881263","title":"RBC Capital Adjusts Price Target on BeOne Medicines to $395 From $374, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881263?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:43","pubTimestamp":1762526591,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. Sponsored ADR (ONC) has an average rating of buy and mean price target of $387.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581886428","title":"BeOne Medicines Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886428?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:08","pubTimestamp":1762524480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 09:08 ET (14:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581009994","title":"BeOne Medicines price target raised to $396 from $348 at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009994?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:55","pubTimestamp":1762512943,"startTime":"0","endTime":"0","summary":"Citizens JMP raised the firm’s price target on BeOne Medicines (ONC) to $396 from $348 and keeps an Outperform rating on the shares. BeOne Medicine...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-price-target-raised-to-396-from-348-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-price-target-raised-to-396-from-348-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581021149","title":"BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581021149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581021149?lang=en_us&edition=fundamental","pubTime":"2025-11-07 11:25","pubTimestamp":1762485919,"startTime":"0","endTime":"0","summary":"Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on BeOne Medicines. The associated price target is $424.00. Yaron Werber has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/beone-medicines-strong-market-position-and-promising-growth-prospects-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/beone-medicines-strong-market-position-and-promising-growth-prospects-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581255640","title":"BeOne Medicines Returns to Profit in Q3 as Revenue Jumps 41%; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581255640","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581255640?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:59","pubTimestamp":1762480782,"startTime":"0","endTime":"0","summary":"BeOne Medicines  returned to an attributable profit of $124.8 million in the third quarter from a loss of $121.4 million in the year-ago period, according to a Thursday filing with the Hong Kong bourse.Shares jumped 3% in Hong Kong and 1% in Shanghai during morning trading on Friday.The biopharmaceutical company reported earnings per share of $0.08, reversing the loss per share of $0.09 in the prior-year period.Total revenue jumped 41% year over year to $1.41 billion from $1 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581069135","title":"BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; Lifts Lower-End of Fiscal 2025 Revenue Outlook Range","url":"https://stock-news.laohu8.com/highlight/detail?id=2581069135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581069135?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:31","pubTimestamp":1762428712,"startTime":"0","endTime":"0","summary":"BeOne Medicines  reported Q3 adjusted earnings Thursday of $2.65 per diluted American depositary share, up from $0.48 a year earlier.Analyst estimates were not readily available for comparison.Total revenue for the quarter ended Sept. 30 was $1.41 billion, up from $1 billion a year earlier.Analysts surveyed by FactSet expected $1.37 billion.The company said it now expects 2025 total revenue in the range of $5.1 billion to $5.3 billion, compared with its prior range of $5 billion to $5.3 billion. Analysts polled by FactSet expect $5.22 billion.Shares of the company were up more than 1% in recent premarket activity on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581066250","title":"GUIDANCE: (ONC) BeOne Medicines Expects Full Year 2025 Sales Range $5.1B - $5.3B, vs. FactSet Est of $5.22B","url":"https://stock-news.laohu8.com/highlight/detail?id=2581066250","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581066250?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:13","pubTimestamp":1762427631,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ONC) BeOne Medicines Expects Full Year 2025 Sales Range $5.1B - $5.3B, vs. FactSet Est of $5.22B","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580285366","title":"What Everest Medicines (SEHK:1952)'s Exclusive VIS-101 Ophthalmology License Means for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2580285366","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580285366?lang=en_us&edition=fundamental","pubTime":"2025-11-02 15:38","pubTimestamp":1762069129,"startTime":"0","endTime":"0","summary":"In late October 2025, Everest Medicines announced it had acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a bifunctional biologic for wet AMD, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and Southeast Asia through a collaboration with Visara, Inc.\nThis marks Everest Medicines' entry into ophthalmology, adding a late-stage asset expected to be Phase-3-ready in 2026 and enhancing its portfolio diversification...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/what-everest-medicines-sehk1952s-exclusive-vis-101-ophthalmo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/what-everest-medicines-sehk1952s-exclusive-vis-101-ophthalmo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","BK4588","BK4585","01952","MDCO","BK1574","VIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580442202","title":"Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2580442202","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580442202?lang=en_us&edition=fundamental","pubTime":"2025-11-01 09:44","pubTimestamp":1761961491,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead.\nSee our latest analysis for Everest Medicines.\nEverest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4588","VIS","BK1161","BK4585","MDCO","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579656111","title":"Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2579656111","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579656111?lang=en_us&edition=fundamental","pubTime":"2025-10-30 11:05","pubTimestamp":1761793500,"startTime":"0","endTime":"0","summary":"Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million  and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million  in potential milestones; plus tied royalties on net sales.VIS-101 is a novelbifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 is anticipated to be Phase 3-ready in 2026.By leveraging Everest Medicines' strong clinical development and commercialization platform, both parties will collaborate closely to efficiently advance the clinical development and commercialization of VIS-101 in China and across Asia, acc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-acquires-exclusive-greater-china-and-other-asian-country-rights-to-vis-101-a-novel-bifunctional-biologic-for-serious-eye-disorders-302599223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","MDCO","VIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579158258","title":"NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2579158258","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579158258?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:27","pubTimestamp":1761776820,"startTime":"0","endTime":"0","summary":"NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176984/0/en/NovaBridge-Subsidiary-Visara-Assigns-Its-Exclusive-License-to-Everest-Medicines-for-VIS-101-in-Greater-China-and-Certain-Other-Asian-Countries.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0056508442.USD","LU0127658192.USD","BK4605","BK4585","LU0719512351.SGD","GFS","LU0081259029.USD","VIS","LU0823421333.USD","BK4554","LU1242518931.SGD","LU0390134368.USD","BK4588","BK4141","BK4612","IE00B5949003.HKD","LU1951200564.SGD","LU0979878070.USD","BK4566","LU1988902786.USD","LU1803068979.SGD","BK4534","LU1861559042.SGD","LU0823434583.USD","LU1861558580.USD","BK4575","LU2360106780.USD","IE0004445239.USD","IE0009356076.USD","IE00BMPRXR70.SGD","BK4614","BK4543","LU1989764664.SGD","BK4529","LU2458330243.SGD","LU0889565833.HKD","IE00BMPRXN33.USD","LU1923623000.USD","LU2250418816.HKD","MDCO","LU2264538146.SGD","LU0823434740.USD","LU0642271901.SGD","LU0198837287.USD","LU0082616367.USD","BK4512","LU2054465674.USD","LU1951198990.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2579866791","title":"BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?","url":"https://stock-news.laohu8.com/highlight/detail?id=2579866791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579866791?lang=en_us&edition=fundamental","pubTime":"2025-10-30 00:32","pubTimestamp":1761755554,"startTime":"0","endTime":"0","summary":"BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines is conducting a Phase 1a/1b clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-new-study-on-bg-75202-a-potential-game-changer-in-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-new-study-on-bg-75202-a-potential-game-changer-in-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4189","BK4588","BK4585","BG","LU0251131958.USD","LU0471298777.SGD","LU2360106947.USD","LU2211817866.USD","LU0251142724.SGD","LU0048573561.USD","MDCO","LU0742534661.SGD","LU0385154629.USD","LU0471298694.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578952358","title":"Market Chatter: Novartis Considers Adding More Medicines to Direct-to-Patient Platform in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2578952358","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578952358?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:55","pubTimestamp":1761656132,"startTime":"0","endTime":"0","summary":"Novartis  is looking to add more medicines to its direct-to-patient platform that is expected to launch in the US on Nov. 1, Reuters reported Tuesday, citing an interview with Chief Executive Vas Narasimhan.No concrete plans have been confirmed, Reuters cited Narasimhan as saying.The CEO added that Novartis was in talks with the US government \"every week\" on lowering medicine costs for patients, according to the report.Novartis did not immediately reply to a request for comment from MT Newswires.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211331839.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK4007","MDCO","BK4585","BK4588","LU0070302665.USD","IE00B4R5TH58.HKD","BK4578","LU0320765489.SGD","IE00B2B36J28.USD","BK4532","IE0009355771.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","NVS","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578895447","title":"GSK Says European Medicines Agency Grants Orphan Drug Designation for Lung Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2578895447","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578895447?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:40","pubTimestamp":1761655204,"startTime":"0","endTime":"0","summary":"GSK  said Tuesday that its experimental therapy, GSK5764227, for treating pulmonary neuroendocrine carcinoma, a cancer category that includes small-cell lung cancer, has received orphan drug designation from the European Medicines Agency.The drugmaker said the designation is based on early clinical data that showed durable responses in patients in an early-stage trial.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4532","BK4007","GSK.UK","LU1829250122.USD","GSK","BK4588","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578983414","title":"SSY Group Wins Chinese Government Bid to Supply Medicines to Healthcare Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2578983414","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578983414?lang=en_us&edition=fundamental","pubTime":"2025-10-28 13:16","pubTimestamp":1761628569,"startTime":"0","endTime":"0","summary":"SSY Group  said it won a bid to supply 12 medicines to government-linked healthcare facilities in China, according to a Hong Kong bourse filing Tuesday.The company had submitted tenders for 14 medicines, of which it won 12, namely diprophylline injection, formoterol fumarate inhalation solution, fluvoxamine maleate tablets, lornoxicam for injection, epinephrine hydrochloride injection, bromhexine hydrochloride injection, multiple electrolyte injection, multiple electrolyte injection , nicorandil tablets, salbutamol sulfate injection, benidipine hydrochloride tablets, and sodium bicarbonate injection.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","BK4185","SSY","02005","XBI","LU2460026573.USD","XLV","BK1191","LU0029874061.USD","BK4588","MDCO","BK4585","HCSG","BK4581","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578606886","title":"SSY Group’s Products Selected in National Medicines Procurement","url":"https://stock-news.laohu8.com/highlight/detail?id=2578606886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578606886?lang=en_us&edition=fundamental","pubTime":"2025-10-28 08:41","pubTimestamp":1761612068,"startTime":"0","endTime":"0","summary":"An update from SSY Group ( ($HK:2005) ) is now available. SSY Group Limited announced that 12 of its products with 14 specifications were selected ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ssy-groups-products-selected-in-national-medicines-procurement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ssy-groups-products-selected-in-national-medicines-procurement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSY","BK4185","MDCO","NHLD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":198,"code":"91000000","status":"200"}]}}